Article: Investment returns elusive for Chongqing Holley after market downturn.

Investment returns elusive for Chongqing Holley after market downturn

Shanghai. June 2. INTERFAX-CHINA - Chongqing Holley Pharm Co. Ltd.

conceded on Saturday that it has failed to meet goals set out in various investment plans over the past few years, attributing such failures to a sluggish artemisinin market.

In August 2003, Chonqing Holley raised RMB 360 million ($51.87 million) to fund a project to expand the company's capacity to extract, process and produce artemisinin, a key ingredient used in the most effective anti-malarial treatments at present.

The expanded artemisinin extraction and processing workshop was originally ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!